Basic Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 28, 2025; 31(4): 93179
Published online Jan 28, 2025. doi: 10.3748/wjg.v31.i4.93179
Bletilla striata polysaccharides alleviate metabolic dysfunction-associated steatotic liver disease through enhancing hepatocyte RelA/ HNF1α signaling
Yi-Huai He, Li-Li Ou, Jin-Lian Jiang, Yun-Fen Chen, Aikedaimu Abudukeremu, Yuan Xue, Mao-Yuan Mu, Wei-Wei Zhong, De-Lin Xu, Xuan-Yu Meng, Ya-Qun Guan
Yi-Huai He, Aikedaimu Abudukeremu, Xuan-Yu Meng, Ya-Qun Guan, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Key Laboratory of Molecular Biology for Endemic Diseases, Department of Pathology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830000, Xinjiang Uyghur Autonomous Region, China
Yi-Huai He, Li-Li Ou, Jin-Lian Jiang, Yun-Fen Chen, Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou Province, China
Yuan Xue, Department of Liver Diseases, Third People’s Hospital of Changzhou, Changzhou 213000, Jiangsu Province, China
Mao-Yuan Mu, Department of Intervention Radiology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou Province, China
Wei-Wei Zhong, Department of Infectious Diseases, Jingmen Central Hospital, Jingmen 448000, Hubei Province, China
De-Lin Xu, Department of Cell Biology, Zunyi Medical University, Zunyi 563099, Guizhou Province, China
Ya-Qun Guan, Xinjiang Second Medical College, Karamay 834000, Xinjiang Uyghur Autonomous Region, China
Author contributions: He YH, Xu DL, and Guan YQ designed the research study; He YH, Ou LL, Jiang JL, Chen YF, and Abudukeremu A performed the research; Xue Y, Mu MY, Zhong WW, Xu DL, and Meng XY contributed new reagents and analytic tools; He YH, Ou LL, Jiang JL, and Chen YF analyzed the data and wrote the manuscript; Guan YQ revised the manuscript; All authors have read and approved the final manuscript.
Supported by the National Natural Science Foundation of China, No. 32260089; the Science and Technology Research Foundation of Guizhou Province, No. QKHJC-ZK (2022) YB642; the Science and Technology Research Foundation of Hubei Province, No. 2022BCE030; the Science and Technology Research Foundation of Changzhou City, No. CE20225040; the Science and Technology Research Foundation of Zunyi City, No. ZSKHHZ (2022) 344 and No. ZSKHHZ (2022) 360; and WBE Liver Fibrosis Foundation, No. CFHPC2025028.
Institutional review board statement: All human hepatocyte studies were approved by the Medical Ethics Committee of Zunyi Medical University, No. (2023)1-172.
Institutional animal care and use committee statement: All animal studies were approved by the Animal Laboratory Studies Ethics Review Committee of Zunyi Medical University, No. ZMU21-2107-003 and No. ZMU22-2303-029.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: The datasets generated and analyzed during the present study are available from the corresponding author upon reasonable request.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ya-Qun Guan, MD, Professor, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Key Laboratory of Molecular Biology for Endemic Diseases, Department of Pathology, School of Basic Medical Sciences, Xinjiang Medical University, No. 393 Xinyi Road, Urumqi 830000, Xinjiang Uyghur Autonomous Region, China. yaqunguan557@xjmu.edu.cn
Received: February 21, 2024
Revised: October 15, 2024
Accepted: November 14, 2024
Published online: January 28, 2025
Processing time: 312 Days and 21 Hours
Core Tip

Core Tip: This study aimed to investigate the therapeutic effects and mechanisms of Bletilla striata polysaccharides (BSP) on metabolic dysfunction-associated steatotic liver disease (MASLD). Treatment with BSP ameliorates MASLD by enhancing the nuclear factor kappa B p65 (RelA)/hepatocyte nuclear factor-1 alpha (HNF1α) signaling in hepatocytes, which remodels ER stress and oxidative stress responses, and reduces lipid metabolism disorders, and necroptosis. The results suggest that targeting hepatocyte RelA/HNF1α signaling may be a new intervention for treating MASLD, and BSP may be a potential reagent for the treatment of MASLD.